What the pilot found
Twenty older adults with mild cognitive impairment were randomized to NR or placebo in a ten-week pilot. Blood NAD increased with NR, and adverse-event reporting did not differ between groups. Cognitive and psychometric measures remained stable. The study did not demonstrate improved cognition. [1]
Researchers reported a reduction in blood flow in parts of the default mode network and exploratory epigenetic findings. They explicitly noted that the blood-flow significance would not survive correction for multiple comparisons. Those findings should not be presented as confirmed brain rejuvenation or a demonstrated harmful effect. [1]
Imaging direction does not explain itself
A change on a brain-imaging measure can sound impressive without being easy to interpret. A reader should not assume that more flow is always a benefit or less flow always a harm in every measured region and context. The paper’s clinical outcomes and statistical limitations matter.
When a seller highlights a brain image, ask what the assigned intervention changed on the trial’s cognitive tests. If the cognitive result was null, that deserves at least as much prominence as an exploratory imaging observation.
This also prevents selective storytelling in the opposite direction. An uncertain imaging result should not be used to make an unsupported alarm claim. The honest conclusion is narrower: this small study did not establish cognitive benefit, and exploratory findings require confirmation.
Multiple comparisons are part of the result
When many brain regions or laboratory measures are examined, some favorable-looking differences may arise by chance. A paper’s qualification about multiplicity is therefore substantive, not a technical footnote to delete from a consumer summary.
For your notes, separate the prespecified cognitive outcome from imaging and epigenetic exploration. Keep the follow-up length beside each. A short pilot can support feasibility and help design a larger experiment without determining whether progression of a cognitive disorder is altered.
The later NR study of cognition and pTau217 asks related questions with a different design. Reading them together is useful, but a positive marker in one paper does not retroactively create a cognitive benefit in another.
Concerns about memory deserve assessment in their own right. This article does not provide a diagnostic test or a supplement treatment plan. Its purpose is to preserve the distinction between a biological response, an exploratory imaging signal and a meaningful cognitive outcome. For the broader framework, see biomarkers versus benefits. That distinction is central to understanding what this pilot contributes and what it leaves unresolved. For cognition claims, the direct test result should be easier to find than an exploratory image or clock score.